Microbot Medical has received a Canadian patent for an adaptor that connects the proximal end of a surgical tool—such as a guidewire or microcatheter—to a motorized robotic surgical device. The award adds to the company’s intellectual-property portfolio as it seeks to protect technology associated with its LIBERTY endovascular robotic system and pursue expansion into additional markets.
The announcement concerns intellectual-property protection, not a new product launch or regulatory clearance. Microbot said it has U.S. and Israeli clearances for LIBERTY and is seeking clearances in other markets.
- The Canadian patent covers an adaptor for coupling elongated surgical tools to a motorized robotic system. The company did not provide further details about the patent’s scope or duration.
- Microbot’s portfolio now includes 45 issued patents and 48 pending patent applications worldwide. Of the issued patents, 21 are in North America. Pending applications are not granted patents.
- The company says its patent strategy is intended to protect and help monetize its technology and support potential future market expansion. It cited additional regulatory clearances as part of that strategy.
- LIBERTY is described by Microbot as a single-use, remotely operated system for peripheral endovascular procedures. The company says it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
The Canadian award adds a layer of patent protection, but it does not itself authorize sales in Canada or demonstrate commercial adoption. Microbot’s stated expansion plans remain dependent in part on obtaining regulatory clearances in additional markets.